Briumvi vs Mabthera: Side-by-Side Comparison
Quick answer: Briumvi and Mabthera are both anti-cd20 monoclonal antibody used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Briumvi | Mabthera |
|---|---|---|
| Drug class | Anti-CD20 monoclonal antibody | Anti-CD20 monoclonal antibody |
| ATC code | L04AA | L01FA01 |
| Primary indications | Relapsing forms of multiple sclerosis | Non-Hodgkin lymphoma, Chronic lymphocytic leukemia |
| Mechanism | Ublituximab is a glycoengineered anti-CD20 monoclonal antibody that depletes B-cells via enhanced antibody-dependent cellular cytotoxicity | Chimeric monoclonal antibody targeting CD20 on B cells causing B-cell depletion via ADCC, CDC, and apoptosis |
| Common dose | 150 mg IV initial, then 450 mg infusions per dosing schedule | Rituximab 375 mg/m² IV weekly or 1000 mg IV every 2 weeks |
| Detail page | Briumvi details → | Mabthera details → |
How to choose between Briumvi and Mabthera
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Anti-CD20 monoclonal antibody on iMedic · Briumvi full details · Mabthera full details
Frequently asked questions
Is Briumvi better than Mabthera?
Neither is universally 'better.' They are both anti-cd20 monoclonal antibody with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Briumvi to Mabthera?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Briumvi and Mabthera have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Briumvi and Mabthera available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.